Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301

Cho, Byoung ChulByoung ChulChoAhn, Myung-JuMyung-JuAhnKang, Jin HyoungJin HyoungKangSoo, Ross ARoss ASooReungwetwattana, ThanyananThanyananReungwetwattanaCHIH-HSIN YANGCicin, IrfanIrfanCicinKim, Dong-WanDong-WanKimWu, Yi-LongYi-LongWuLu, ShunShunLuLee, Ki HyeongKi HyeongLeePang, Yong-KekYong-KekPangZimina, AnastasiaAnastasiaZiminaFong, Chin HengChin HengFongPoddubskaya, ElenaElenaPoddubskayaSezer, AhmetAhmetSezerHow, Soon HinSoon HinHowDanchaivijitr, PongwutPongwutDanchaivijitrKim, YuKyungYuKyungKimLim, YejiYejiLimAn, TaewonTaewonAnLee, HanaHanaLeeByun, Hae MiHae MiByunZaric, BojanBojanZaric2023-09-252023-09-252023-09-100732-183X1527-7755https://scholars.lib.ntu.edu.tw/handle/123456789/635776Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients with EGFR-mutated (exon 19 deletion [ex19del]/L858R) locally advanced or metastatic non-small-cell lung cancer (NSCLC).en[SDGs]SDG3Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301journal article10.1200/JCO.23.00515373795022-s2.0-85170112349https://api.elsevier.com/content/abstract/scopus_id/85170112349